Tokio Marine Asset Management Co. Ltd. Has $1.84 Million Stock Position in Becton, Dickinson and Company (NYSE:BDX)

Tokio Marine Asset Management Co. Ltd. raised its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 9.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,636 shares of the medical instruments supplier’s stock after buying an additional 642 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Becton, Dickinson and Company were worth $1,841,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also modified their holdings of the business. Ameriprise Financial Inc. boosted its stake in Becton, Dickinson and Company by 6.4% in the second quarter. Ameriprise Financial Inc. now owns 5,055,354 shares of the medical instruments supplier’s stock worth $1,181,483,000 after purchasing an additional 302,893 shares in the last quarter. Massachusetts Financial Services Co. MA increased its position in Becton, Dickinson and Company by 1.8% in the 2nd quarter. Massachusetts Financial Services Co. MA now owns 4,905,114 shares of the medical instruments supplier’s stock valued at $1,146,374,000 after acquiring an additional 87,230 shares in the last quarter. Bank of New York Mellon Corp increased its position in Becton, Dickinson and Company by 8.5% in the 2nd quarter. Bank of New York Mellon Corp now owns 4,412,163 shares of the medical instruments supplier’s stock valued at $1,031,167,000 after acquiring an additional 346,720 shares in the last quarter. Clearbridge Investments LLC raised its stake in shares of Becton, Dickinson and Company by 3.1% in the second quarter. Clearbridge Investments LLC now owns 2,984,524 shares of the medical instruments supplier’s stock worth $697,513,000 after acquiring an additional 89,157 shares during the last quarter. Finally, First Eagle Investment Management LLC grew its stake in shares of Becton, Dickinson and Company by 32.5% during the second quarter. First Eagle Investment Management LLC now owns 2,803,255 shares of the medical instruments supplier’s stock valued at $655,149,000 after purchasing an additional 688,296 shares during the last quarter. 86.97% of the stock is owned by institutional investors and hedge funds.

Becton, Dickinson and Company Stock Performance

Shares of Becton, Dickinson and Company stock opened at $227.23 on Friday. The stock’s fifty day simple moving average is $236.56 and its 200 day simple moving average is $235.10. The company has a current ratio of 1.17, a quick ratio of 0.74 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $65.68 billion, a PE ratio of 38.25, a PEG ratio of 1.72 and a beta of 0.43. Becton, Dickinson and Company has a 12 month low of $218.75 and a 12 month high of $249.89.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings data on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The business had revenue of $5.44 billion for the quarter, compared to analysts’ expectations of $5.38 billion. During the same quarter in the previous year, the business posted $3.42 EPS. Becton, Dickinson and Company’s revenue for the quarter was up 6.9% on a year-over-year basis. On average, research analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, December 31st. Investors of record on Monday, December 9th will be paid a $1.04 dividend. The ex-dividend date is Monday, December 9th. This is a positive change from Becton, Dickinson and Company’s previous quarterly dividend of $0.95. This represents a $4.16 dividend on an annualized basis and a yield of 1.83%. Becton, Dickinson and Company’s dividend payout ratio is presently 63.97%.

Analysts Set New Price Targets

BDX has been the topic of several research reports. Raymond James reduced their price objective on Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday, August 2nd. Evercore ISI upped their target price on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the company an “outperform” rating in a research report on Tuesday, October 1st. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Citigroup upgraded shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the company from $255.00 to $275.00 in a report on Tuesday, October 1st. Finally, Stifel Nicolaus lifted their target price on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a report on Friday, July 26th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $283.00.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.